Related Experiment Video
Updated: May 22, 2026
03:08
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
Using PharmGKB to train text mining approaches for identifying potential gene targets for pharmacogenomic studies
S Pakhomov1, B T McInnes, J Lamba
1College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA. pakh0002@umn.edu
Journal of Biomedical Informatics
|May 9, 2012
Summary
This study demonstrates a feasible text mining approach using PharmGKB (Pharmacogenomics Knowledgebase) and MEDLINE abstracts to identify novel gene targets for pharmacogenomics research.
Area of Science:
- Pharmacogenomics
- Bioinformatics
- Computational Biology
Background:
- Pharmacogenomics research aims to understand drug responses based on genetic variations.
- Identifying gene targets is crucial for pathway-driven pharmacogenomics.
- Existing methods may not identify all relevant gene targets.
Purpose of the Study:
- To assess the feasibility of using PharmGKB and MEDLINE abstracts for text mining.
- To develop a predictive model for identifying potential gene targets.
- To discover novel gene targets for pathway-driven pharmacogenomics.
Main Methods:
- Utilized manually curated drug-gene relations from PharmGKB to train a support vector machine (SVM) model.
- Applied the trained SVM model to MEDLINE abstracts for prospective gene target identification.
- Conducted quantitative and qualitative analyses of the model's performance and suggested gene targets.
Main Results:
- The SVM classifier achieved 85% sensitivity and 69% specificity.
- The approach identified relevant gene targets not initially anticipated by expert reviewers.
- Identified gene targets were relevant to carbamazepine, lamivudine, and zidovudine.
Conclusions:
- The text mining approach using PharmGKB and MEDLINE abstracts is feasible for pharmacogenomics research.
- This method can identify novel gene targets missed by other approaches.
- It serves as a valuable tool for advancing pathway-driven pharmacogenomics.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...